SEP 2022

EyeWorld is the official news magazine of the American Society of Cataract & Refractive Surgery.

Issue link: https://digital.eyeworld.org/i/1475139

Contents of this Issue


Page 90 of 90

Improved near and intermediate vision without compromising distance vision † 1 Go ahead. Read the fine print. V UIT Y ® MAY B E A B LE TO HELP. 1,2 In studies, VUITY ® improved the ability to read an additional 3 lines or more on a near vision eye chart.† AN E YE D RO P FO R PRESBYO PIA? 1,2 © 2022 AbbVie Inc. North Chicago, IL US-VUI-220308 June 2022 INDICATION VUITY® (pilocarpine hydrochloride ophthalmic solution) 1.25% is indicated for the treatment of presbyopia in adults. IMPORTANT SAFETY INFORMATION CONTRAINDICATIONS VUITY is contraindicated in patients with known hypersensitivity to any ingredient in the formulation. WARNINGS AND PRECAUTIONS Patients should be advised to exercise caution in night driving and other hazardous occupations in poor illumination. In addition, miotics may cause accommodative spasm. Patients should be advised not to drive or use machinery if vision is not clear. Rare cases of retinal detachment have been reported with other miotics when used in susceptible patients and those with pre-existing retinal disease. Patients should be advised to seek immediate medical care with sudden onset of vision loss. VUITY is not recommended to be used when iritis is present because adhesions (synechiae) may form between the iris and lens. Contact lens wearers should be advised to remove their lenses prior to the instillation of VUITY and to wait 10 minutes after dosing before reinserting their contact lenses. To prevent eye injury or contamination, care should be taken to avoid touching the dispensing bottle to the eye or to any other surface. ADVERSE REACTIONS The most common adverse reactions (>5%) reported in clinical trials were headache and conjunctival hyperemia. Please see Brief Summary of full Prescribing Information on the accompanying page or reverse side. † Primary endpoint was the proportion of participants gaining ≥3 lines in mesopic, high-contrast, binocular, distance-corrected near visual acuity (DCNVA) without losing more than 1 line (5 letters) of corrected distance visual acuity (CDVA) with the same refractive correction at Day 30, Hour 3. 1 Change from baseline in photopic, high-contrast, binocular, DCIVA at Day 30, Hour 3 was a prespecified secondary endpoint. 3 References: 1. VUITY Prescribing Information. 2. Price FW, et al. Ophthalmol Sci. 2021; doi: https://doi.org/10.106/j.xops.2021.100065. 3. Data on File, ABVRRTI73127. VuityPro.com/efficacy Not an actual patient

Articles in this issue

Links on this page

Archives of this issue

view archives of Eyeworld - SEP 2022